Modeling in Early Stages of Technology Development: Is an Iterative Approach Needed?; Comment on “Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling”

Document Type: Commentary

Author

University of York, York, UK

Abstract

A recent paper by Grutters et al makes the case for early health economic modeling in the development of health technologies. A number of examples of the value of early modeling are given, with analyses being performed at different stages in the development of several non-drug health technologies. This commentary acknowledges the contribution of the paper by Grutters et al and argues for an iterative and integrated approach to early modeling, assessing the cost-effectiveness of the technology, the value of future research and the interaction with the manufacturer’s pricing and revenue expectations.

Keywords

Main Subjects


  1. Grutters JPC, Govers T, Nijboer J, Tummers M, van der Wilt GJ, Rovers MM. Problems and promises of health technologies: the role of early health economic modeling. Int J Health Policy Manag. 2019;8(10):575-582. doi:10.15171/ijhpm.2019.36
  2. Backhouse ME, Wonder M, Hornby E, Kilburg A, Drummond M, Mayer FK. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study. Value Health. 2011;14(4):608-615. doi:10.1016/j.jval.2010.11.011
  3. Rothery C, Claxton K, Palmer S, Epstein D, Tarricone R, Sculpher M. Characterising uncertainty in the assessment of medical devices and determining future research needs. Health Econ. 2017;26 Suppl 1:109-123. doi:10.1002/hec.3467
  4. Sculpher M, Drummond M, Buxton M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy. 1997;2(1):26-30. doi:10.1177/135581969700200107
  5. Drummond M, Griffin A, Tarricone R. Economic evaluation for devices and drugs--same or different? Value Health. 2009;12(4):402-404. doi:10.1111/j.1524-4733.2008.00476_1.x